Viewing nowNeuropain Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Unimed Pharmaceutical Co., Ltd.

MFDS item code 201109296 · Approved 2011.10.31 · Insurance code 649506030
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medicine is used for treating peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in patients with epilepsy and is effective even when there are secondary general symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, this medication is effective for neuropathic pain, epilepsy, and fibromyalgia treatment.
This medication is administered orally, regardless of food, as pregabalin in the total daily dose divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if mood changes or symptoms of depression appear during treatment, it is essential to consult a doctor immediately. Patients with allergies to any components of this medication or specific genetic lactose metabolism disorders should not take it. Diabetic patients should be cautious as weight gain may require adjustments to blood glucose control medications. If symptoms of severe allergic reactions such as angioedema occur, discontinue the medication immediately and consult medical personnel. Elderly individuals should be careful during the initial doses due to the risk of dizziness or drowsiness leading to falls. Visual disturbances such as blurred vision may occur, and if symptoms persist, consultation with a physician is recommended. Withdrawal symptoms such as insomnia, headache, and anxiety may emerge after discontinuation, so abrupt cessation should be avoided. Patients with a history of drug abuse may have a higher risk of misuse of this medication, so caution is advised during use. Patients with impaired renal function may require dose adjustments. Patients with severely compromised cardiac function should use this medication cautiously. When taking with other drugs that have central nervous system depressant effects, there is an increased risk of drowsiness or respiratory depression, so caution is required. During early pregnancy, it may affect the fetus, so it should generally not be used, except in special circumstances, and women of childbearing age should use effective contraception. Lactating women should consider discontinuing breastfeeding or the medication, as this medication can be transmitted through breast milk. This medication may cause dizziness and drowsiness, so it is advisable to avoid driving or operating hazardous machinery after taking it. Serious skin reactions may occur rarely, so if any unusual symptoms such as rash or swelling appear, inform medical personnel immediately. In the case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, so the prescribed dosage must be followed. Blood dialysis may be necessary if required. Special precautions are necessary for children and the elderly, and children should be kept out of reach of this medication.
Not everyone experiences these, and they can vary from person to person.
This medication can be sensitive to air and moisture, so it must be stored in a tightly closed container. It is advisable to maintain the storage temperature between 15 to 30 degrees Celsius. Proper storage helps preserve the medication's effectiveness over time.
A white or pale yellow powder contained in white hard capsules with white upper and lower parts.
30 capsules/bottle, 200 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.